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Comment on "Pathophysiology of migraine" by professor
PJ Goadsby in August 2012 edition of Ann Indian Acad Neurol
Sir, In his article "Pathophysiology of migraine," in the Ann Indian Acad Neurol 2012 August; 15(Suppl 1):S15-S22, [1] Following points need serious consideration: 1. The author stated "Vascular changes are unrelated to the phase of the attack; indeed blood flow could be reduced or normal during the pain phase." To support this statement, he cited the research carried out by Olesen and the "Copenhagen Group." It is true that the Copenhagen Group found that changes in intracranial regional cerebral blood-flow (rCBF) were unrelated to the severity and timing of migraine pain [2] but this study of the Copenhagen Group had no relevance to extracranial vasodilatation. Olesen's group studied rCBF, not the blood-flow of the extracranial arteries. The use of the Copenhagen Group's observations in this context is misleading. 2. The author has previously claimed, and has now repeated, that migraine occurs without any change in the extracranial vessels. To support this claim, he referred to the work of Schoonman et al., who were able for the first time to accurately measure the diameters of most of the major intracranial and some of the extracranial vessels, both during migraine and interictally, and on left and right sides during unilateral migraine. They showed that none of the vessels measured dilated during migraine. [3] The only part of the extracranial vasculature that Schoonman et al., measured, however, was the last 1 cm of the main trunk of the external carotid artery, which has never been implicated in migraine. Schoonman et al., made no mention of the terminal branches of the external carotid artery as these vessels were not included in their study. The use of Schoonman's study to justify the claim that the terminal branches of the extracranial vessels are not involved in migraine is to misrepresent the results of Schoonman's study. 3. The third serious misrepresentation concerns the author's claim, that the gepant BIBN4096BS is "without vascular effects." Yes, BIBN4096BS does not actively constrict arteries in healthy volunteers, [4] but that is completely different from being without vascular effects in the context of migraine. To substantiate this claim, the author cited Petersen et al., [4] Petersen's article is unambiguous -it clearly states that BIBN4096BS is
Author's reply on Pathophysiology of migraine
Sir, Thank you for sending along correspondence with regard to a recent review. [1] I am grateful for your correspondents' interest. They make three points:
• They comment that citation of data from regional cerebral blood-flow studies [2] to demonstrate a disconnection between migraine pain and vasodilation is insufficient. I would agree. In a wide-reaching review sometimes not all data is cited. It is clear from other work from the same group that superficial temporal artery changes are not seen in migraine triggered by sildenafil, [3] among other examples one could adduce to this point • With regard to magnetic resonance angiography (MRA) work that does not demonstrate any change in extracranial vessel diameter in migraine, [4] the argument regarding vessel size is somewhat circular. While it is possible smaller vessels are the generator of pain; that has not been demonstrated and directly opposes all the more recent pharmacological data. If small vessels are important why does the non-vascular ditan class work? [5, 6] • Your correspondent regards the claim that gepants are without vascular effects as a serious misrepresentation. As your correspondent admits olcegepant is not a vasoconstrictor. [7] The statement made was that olcegepant has no vascular action, not that it stops calcitonin gene-related peptide (CGRP) having vasodilation. Nothing about olcegepant was misrepresented. Your correspondent tendentiously pursues vasodilation with a single example, while ignoring that the gepant data sits with the entirety of the clinical trial literature, conveniently ignoring the ditan data cited above or indeed simple things, such as the data on intravenous aspirin in migraine, [8] again as a non-vascular acute treatment.
May I add on a personal note, whatever reason some may have for developing CGRP receptor antagonists, I can assure you that the first rationale was to look at CGRP release in terms neural mechanisms. [9, 10] Migraine is a brain disorder; [11] the sooner the organ of the disorder receives full focus, the nearer we come to both enhanced understanding and better therapies.
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